Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
  • Oncology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them. If irAEs do develop, it is essential to arrive at an early diagnosis and use aggressive systemic corticosteroids when necessary to prevent life-threatening consequences.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs.
  • Oncology
  • ACPE Pharmacy
  • Participation
02/02/2021
$0.00
This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis.
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
02/05/2021
$0.00
This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF).

Pages